

# Global Gaucher Disease Treatment Market Outlook 2027

<https://marketpublishers.com/r/G991D8BCE4AFEN.html>

Date: March 2020

Pages: 154

Price: US\$ 4,150.00 (Single User License)

ID: G991D8BCE4AFEN

## Abstracts

### Global Gaucher Disease Market Analysis – 2018-2027

Gaucher disease (GD) refers to the accumulation of glucocerebroside in cells and certain organs leading to the enlargement of the liver and spleen. The genetic disorder is caused by a hereditary deficiency of the enzyme glucocerebrosidase and is characterized by bruising, fatigue, anemia and low blood platelet count. The global Gaucher disease market is anticipated to record a CAGR of around 3% over the forecast period, i.e. 2019-2026. Factors such as increasing incidences of Gaucher's disease as well as the increasing focus of the pharmaceutical companies on introducing new products that cater to the treatment of Gaucher disease are anticipated to contribute significantly towards the growth of the global Gaucher disease market. Additionally, increasing concern for the growing incidences of Gaucher disease amongst people around the globe, coupled with the growing support and funding of the government of nations and the rising per capita expenditure on healthcare by several nations around the globe are some of the factors anticipated to drive the growth of the global Gaucher disease market.

The global Gaucher disease market consists of various segments that are segmented by product type, by infusion mode, by clinical type, by end user and by region. The product type segment is further sub-divided into enzyme replacement therapy or ERT and substrate replacement therapy or SRT. Out of these, the enzyme replacement therapy segment, which held a market value of around USD 1400 million in the year 2018, is anticipated to grow with a CAGR of around 3% during the forecast period. On the basis of infusion mode, the market is segmented into intravenous infusion and oral. Out of these segments, the intravenous infusion segment is anticipated to hold the largest market share by the end of 2026 and is anticipated to grow with a CAGR of

around 3% during the forecast period and reach a value of around USD 1600 million by the end of 2026.

Based on region, the global Gaucher disease market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The market in Europe, which had accounted for around 28% share in the year 2018, is estimated to witness a CAGR of around 2% during the forecast period and reach a value of around USD 520 million by the end of 2026.

Some of the affluent industry leaders in the global Gaucher disease market are Protalix Inc., Pfizer Inc., Actelion Pharmaceuticals Ltd., Sanofi and Takeda Pharmaceutical Company Limited.

## Contents

Global Gaucher Disease Market

### **1. INTRODUCTION**

- 1.1. MARKET DEFINITION
- 1.2. PURPOSE OF THE REPORT
- 1.3. CURRENCY
- 1.4. LIMITATIONS
- 1.5. STAKEHOLDERS

### **2. RESEARCH METHODOLOGY**

- 2.1. RESEARCH SCOPE
- 2.2. MARKET SEGMENTATION
- 2.3. RESEARCH APPROACH
  - 2.3.1 TOP-DOWN APPROACH
  - 2.3.2 BOTTOM-UP APPROACH
- 2.4. PRIMARY RESEARCH
- 2.5. SECONDARY RESEARCH
- 2.6. ASSUMPTIONS

### **3. GLOBAL GAUCHER DISEASE MARKET – EXECUTIVE SUMMARY**

- 3.1. SUMMARY

### **4. GLOBAL GAUCHER DISEASE MARKET OVERVIEW**

#### 4.1. MARKET DYNAMICS

##### 4.1.1 DRIVING FORCES

4.1.1.1 Growing incidence of Gaucher disease

4.1.1.2 Increasing governmental support and growing demand for enzyme

replacement therapy for the treatment of rare diseases

##### 4.1.2 RESTRAINING FACTOR

4.1.2.1 High cost of product and therapies

##### 4.1.3 OPPORTUNITY MATRIX

4.1.3.1 Expansion of product portfolio especially in towards Pharmaceutical Products

## **5. INDUSTRY INSIGHTS**

### **5.1. PORTER'S FIVE FORCES ANALYSIS**

5.1.1 BARGAINING POWER OF SUPPLIER

5.1.2 BARGAINING POWER OF BUYER

5.1.3 THREAT OF SUBSTITUTE

5.1.4 THREAT OF NEW ENTRANT

5.1.5 DEGREE OF COMPETITION

### **5.2. VALUE CHAIN ANALYSIS**

## **6. GLOBAL GAUCHER DISEASE MARKET, BY PRODUCT**

### **6.1. OVERVIEW**

## **7. GLOBAL GAUCHER DISEASE MARKET, BY INFUSION MODES**

### **7.1. OVERVIEW**

## **8. GLOBAL GAUCHER DISEASE MARKET, BY DISTRIBUTION CHANNEL**

### **8.1. OVERVIEW**

## **9. GLOBAL GAUCHER DISEASE MARKET, BY CLINICAL TYPE**

### **9.1. OVERVIEW**

## **10. NORTH AMERICA GAUCHER DISEASE MARKET**

### **10.1. OVERVIEW**

10.1.1.1 North America Market Analysis, By Product Type

10.1.1.2 North America Market Analysis, By Intake Mode

10.1.1.3 North America Market Analysis, By Clinical Types

10.1.1.4 North America Market Analysis, By End-Users

### **10.2. U.S.**

10.2.1.1 U.S. Market Analysis, By Product Type

10.2.1.2 U.S. Market Analysis, By Intake Mode

10.2.1.3 U.S. Market Analysis, By Clinical Types

10.2.1.4 U.S. Market Analysis, By End-Users

### **10.3. CANADA**

- 10.3.1.1 Canada Market Analysis, By Product Type
- 10.3.1.2 Canada Market Analysis, By Intake Mode
- 10.3.1.3 Canada Market Analysis, By Clinical Types
- 10.3.1.4 Canada Market Analysis, By End-Users

## **11. LATIN AMERICA GAUCHER DISEASE MARKET**

### **11.1. OVERVIEW**

- 11.1.1.1 Latin America Market Analysis, By Product Type
- 11.1.1.2 Latin America Market Analysis, By Intake Mode
- 11.1.1.3 Latin America Market Analysis, By Clinical Types
- 11.1.1.4 Latin America Market Analysis, By End-Users

### **11.2. BRAZIL**

- 11.2.1.1 Brazil Market Analysis, By Product Type
- 11.2.1.2 Brazil Market Analysis, By Intake Mode
- 11.2.1.3 Brazil Market Analysis, By Clinical Types
- 11.2.1.4 Brazil Market Analysis, By End-Users

### **11.3. MEXICO**

- 11.3.1.1 Mexico Market Analysis, By Product Type
- 11.3.1.2 Mexico Market Analysis, By Intake Mode
- 11.3.1.3 Mexico Market Analysis, By Clinical Types
- 11.3.1.4 Mexico Market Analysis, By End-Users

### **11.4. ARGENTINA**

- 11.4.1.1 Argentina Market Analysis, By Product Type
- 11.4.1.2 Argentina Market Analysis, By Intake Mode
- 11.4.1.3 Argentina Market Analysis, By Clinical Types
- 11.4.1.4 Argentina Market Analysis, By End-Users

## **12. EUROPE GAUCHER DISEASE MARKET**

### **12.1. OVERVIEW**

- 12.1.1.1 Europe Market Analysis, By Product Type
- 12.1.1.2 Europe Market Analysis, By Intake Mode
- 12.1.1.3 Europe Market Analysis, By Clinical Types
- 12.1.1.4 Europe Market Analysis, By End-Users

### **12.2. GERMANY**

- 12.2.1.1 Germany Market Analysis, By Product Type
- 12.2.1.2 Germany Market Analysis, By Intake Mode
- 12.2.1.3 Germany Market Analysis, By Clinical Types

12.2.1.4 Germany Market Analysis, By End-Users

### 12.3. UNITED KINGDOM

12.3.1.1 United Kingdom Market Analysis, By Product Type

12.3.1.2 United Kingdom Market Analysis, By Intake Mode

12.3.1.3 United Kingdom Market Analysis, By Clinical Types

12.3.1.4 United Kingdom Market Analysis, By End-Users

### 12.4. FRANCE

12.4.1.1 France Market Analysis, By Product Type

12.4.1.2 France Market Analysis, By Intake Mode

12.4.1.3 France Market Analysis, By Clinical Types

12.4.1.4 France Market Analysis, By End-Users

### 12.5. ITALY

12.5.1.1 Italy Market Analysis, By Product Type

12.5.1.2 Italy Market Analysis, By Intake Mode

12.5.1.3 Italy Market Analysis, By Clinical Types

12.5.1.4 Italy Market Analysis, By End-Users

### 12.6. SPAIN

12.6.1.1 Spain Market Analysis, By Product Type

12.6.1.2 Spain Market Analysis, By Intake Mode

12.6.1.3 Spain Market Analysis, By Clinical Types

12.6.1.4 Spain Market Analysis, By End-Users

### 12.7. TURKEY

12.7.1.1 Turkey Market Analysis, By Product Type

12.7.1.2 Turkey Market Analysis, By Intake Mode

12.7.1.3 Turkey Market Analysis, By Clinical Types

12.7.1.4 Turkey Market Analysis, By End-Users

### 12.8. RUSSIA

12.8.1.1 Russia Market Analysis, By Product Type

12.8.1.2 Russia Market Analysis, By Intake Mode

12.8.1.3 Russia Market Analysis, By Clinical Types

12.8.1.4 Russia Market Analysis, By End-Users

## 13. ASIA PACIFIC GAUCHER DISEASE MARKET

### 13.1. OVERVIEW

13.1.1.1 Asia Pacific Market Analysis, By Product Type

13.1.1.2 Asia Pacific Market Analysis, By Intake Mode

13.1.1.3 Asia Pacific Market Analysis, By Clinical Types

13.1.1.4 Asia Pacific Market Analysis, By End-Users

## 13.2. CHINA

- 13.2.1.1 China Market Analysis, By Product Type
- 13.2.1.2 China Market Analysis, By Intake Mode
- 13.2.1.3 China Market Analysis, By Clinical Types
- 13.2.1.4 China Market Analysis, By End-Users

## 13.3. INDIA

- 13.3.1.1 India Market Analysis, By Product Type
- 13.3.1.2 India Market Analysis, By Intake Mode
- 13.3.1.3 India Market Analysis, By Clinical Types
- 13.3.1.4 India Market Analysis, By End-Users

## 13.4. JAPAN

- 13.4.1.1 Japan Market Analysis, By Product Type
- 13.4.1.2 Japan Market Analysis, By Intake Mode
- 13.4.1.3 Japan Market Analysis, By Clinical Types
- 13.4.1.4 Japan Market Analysis, By End-Users

## 13.5. SOUTH KOREA

- 13.5.1.1 South Korea Market Analysis, By Product Type
- 13.5.1.2 South Korea Market Analysis, By Intake Mode
- 13.5.1.3 South Korea Market Analysis, By Clinical Types
- 13.5.1.4 South Korea Market Analysis, By End-Users

## 13.6. AUSTRALIA

- 13.6.1.1 Australia Market Analysis, By Product Type
- 13.6.1.2 Australia Market Analysis, By Intake Mode
- 13.6.1.3 Australia Market Analysis, By Clinical Types
- 13.6.1.4 Australia Market Analysis, By End-Users

## **14. MIDDLE EAST AND AFRICA (MEA) GAUCHER DISEASE MARKET**

### 14.1. OVERVIEW

- 14.1.1.1 MEA Market Analysis, By Product Type
- 14.1.1.2 MEA Market Analysis, By Intake Mode
- 14.1.1.3 MEA Market Analysis, By Clinical Types
- 14.1.1.4 MEA Market Analysis, By End-Users

### 14.2. SOUTH AFRICA

- 14.2.1.1 South Africa Market Analysis, By Product Type
- 14.2.1.2 South Africa Market Analysis, By Intake Mode
- 14.2.1.3 South Africa Market Analysis, By Clinical Types
- 14.2.1.4 South Africa Market Analysis, By End-Users

### 14.3. SAUDI ARABIA

- 14.3.1.1 Saudi Arabia Market Analysis, By Product Type
- 14.3.1.2 Saudi Arabia Market Analysis, By Intake Mode
- 14.3.1.3 Saudi Arabia Market Analysis, By Clinical Types
- 14.3.1.4 Saudi Arabia Market Analysis, By End-Users

#### 14.4. ISRAEL

- 14.4.1.1 Israel Market Analysis, By Product Type
- 14.4.1.2 Israel Market Analysis, By Intake Mode
- 14.4.1.3 Israel Market Analysis, By Clinical Types
- 14.4.1.4 Israel Market Analysis, By End-Users

#### 14.5. UAE

- 14.5.1.1 UAE Market Analysis, By Product Type
- 14.5.1.2 UAE Market Analysis, By Intake Mode
- 14.5.1.3 UAE Market Analysis, By Clinical Types
- 14.5.1.4 UAE Market Analysis, By End-Users

### **15. COMPANY PROFILES**

#### 15.1. PROTALIX BIOTHERAPEUTICS INC

- 15.1.1 COMPANY OVERVIEW
- 15.1.2 FINANCIAL PERFORMANCE
- 15.1.3 PRODUCT PORTFOLIO

#### 15.2. PFIZER INC

- 15.2.1 COMPANY OVERVIEW
- 15.2.2 FINANCIAL PERFORMANCE
- 15.2.3 PRODUCT PORTFOLIO

#### 15.3. ACTELION PHARMACEUTICALS LTD

- 15.3.1 COMPANY OVERVIEW
- 15.3.2 PRODUCT PORTFOLIO
- 15.3.3 RECENT DEVELOPMENT

#### 15.4. SANOFI SA

- 15.4.1 COMPANY OVERVIEW
- 15.4.2 FINANCIAL PERFORMANCE
- 15.4.3 PRODUCT PORTFOLIO

#### 15.5. TAKEDA PHARMACEUTICAL CO LTD

- 15.5.1 COMPANY OVERVIEW
- 15.5.2 FINANCIAL PERFORMANCE
- 15.5.3 PRODUCT PORTFOLIO
- 15.5.4 RECENT DEVELOPMENT



## I would like to order

Product name: Global Gaucher Disease Treatment Market Outlook 2027

Product link: <https://marketpublishers.com/r/G991D8BCE4AFEN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G991D8BCE4AFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970